XT
MGX icon

XTX Topco’s Metagenomi Therapeutics MGX Stock Holding History

XTX Topco’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.3K Buy
55,707
+15,125
+37% +$20.2K ﹤0.01% 3641
2026
Q1 		$54.4K Sell
40,582
-28,412
-41% -$44.1K ﹤0.01% 3293
2025
Q4 		$112K Buy
68,994
+53,778
+353% +$116K ﹤0.01% 2605
2025
Q3 		$36.1K Buy
+15,216
New +$30.9K ﹤0.01% 2230
2024
Q3 		– Sell
-16,244
Closed -$66.3K – 2701
2024
Q2 		$66.3K Buy
+16,244
New +$112K 0.01% 1478

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

XTX Topco's MGX Position: Q2 2026 in Review

XTX Topco increased its Metagenomi Therapeutics (MGX) stake by 37% in Q2 2026, buying an estimated $20.2K and bringing the position to 55,707 shares worth $66.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3641.

XTX Topco first reported a position in MGX in Q2 2024 and has held it in 5 quarters since. The position peaked at $112K in Q4 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • XTX Topco held 55,707 shares of Metagenomi Therapeutics worth $66.3K as of Q2 2026.
  • XTX Topco bought 15,125 Metagenomi Therapeutics shares in Q2 2026, an estimated $20.2K.
  • Metagenomi Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3641 holding.
  • XTX Topco first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • XTX Topco's Metagenomi Therapeutics position peaked at $112K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.